Achievement of guideline-defined treatment goals in primary care: The German Coronary Risk Management (CoRiMa) study

European Heart Journal

Volumn 28, Issue 24, 2007, Pages 3051-3058

  Geller, Johann Christoph ^a   Cassens, Sven ^b   Brosz, Mathias ^c   Keil, Ulrich ^d   Bernarding, Johannes ^e   Kropf, Siegfried ^e   Bierwirth, Ralph A ^f   Lippmann Grob, Bernhard ^g   Schultheiss, Heinz Peter ^h   Schlüter, Klaus ^b   Pels, Klaus ^h  

^a Division of Cardiology   (Germany)

^b Pfizer Pharma GmbH   (Germany)

^c StatConsult GmbH   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e University Hospitals Magdeburg   (Germany)

^f Diabetes Center   (Germany)

^g Diabetes Center   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Coronary artery disease; Diabetes; Hyperlipidaemia; Hypertension; Primary care; Risk factors; Risk modelling

Indexed keywords

HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK MANAGEMENT; RISK REDUCTION;

CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EPIDEMIOLOGIC METHODS; FAMILY PRACTICE; FEMALE; GERMANY; GUIDELINE ADHERENCE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE;

EID: 37149057185     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehm520     Document Type: Article

References (51)

1. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997;18:1231-1248.
2. Ezzati M, Lopez AD, Rodgers A, Vander HS, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002;360: 1347-1360.
3. American Diabetes Association. Clinical practice recommendations 1997. Diabetes Care 1997;20(Suppl. 1):S1-S70.
4. Meyer J, Breithardt G, Erbel R, Erdmann E, Gohlke H, Hanrath P, Sonntag F, Steinbeck G. Leitlinie: Koronare Herzkrankheit/Angina pectoris. Z Kardiol 1998;87:907-911.
5. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-183.
6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
7. Leitlinie für die Prävention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie. Dtsch Med Wochenschr 2001;126(Suppl. 4): S201-S238.
8. DeBacker G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger CV, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-1610.
9. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053.
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
11. Brosz M, Golm A, Milbradt U, Gerressen W, Schlüter K. Analysen zur Versorgungssituation auf Basis ärztlich erhobener Routinedaten aus Praxisverwaltungssystemen. Gesundh Ökon Qual Manag 2007;12:225-228.
12. Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D'Agostino RB, Levy D. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004;94:20-24.
13. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24: 987-1003.
14. Keil U, Fitzgerald AP, Gohlke H, Wellmann J, Hense HW. Risk Stratification of Cardiovascular Diseases in Primary Prevention - The New SCORE Deutschland Risk Charts. Dtsch Arztebl 2005;102:1808-1812.
15. de Lusignan S, Hague N, van VJ, Kumarapeli P. Routinely-collected general practice data are complex, but with systematic processing can be used for quality improvement and research. Inform Prim Care 2006; 14:59-66.
16. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357:995-1001.
17. Arnett DK, Jacobs DR Jr, Luepker RV, Blackburn H, Armstrong C, Claas SA. Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002. Circulation 2005;112:3884-3891.
18. Berlowitz DR, Ash AS, Hickey EC, Glickman M, Friedman R, Kader B. Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care 2003;26:355-359.
19. Boersma E, Keil U, De BD, De BG, Pyorala K, Poldermans D, Leprotti C, Pilotto L, de SE, Deckers JW, Heidrich J, Sans S, Kotseva K, Wood D, Ambrosio GB. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 2003;21: 1831-1840.
20. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003;107:2185-2189.
21. Fornengo P, Bruno G, De SA, Arcari R, Pisu E, Pagano G. Low adherence of General Practitioners to National Cholesterol Education Program guidelines for the management of hyperlipidaemia. Diabetes Nutr Metab 2000;13:263-268.
22. Gaw A. The care gap: underuse of statin therapy in the elderly. Int J Clin Pract 2004;58:777-785.
23. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290:199-206.
24. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002;19:596- 604.
25. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82:61-65.
26. Lloyd-Jones DM, Evans JC, Larson MG, Levy D. Treatment and control of hypertension in the community: a prospective analysis. Hypertension 2002;40:640-646.
27. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999;14:711-717.
28. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998;158: 1238-1244.
29. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006; 113:203-212.
30. Olson KL, Bungard TJ, Tsuyuki RT. Cholesterol risk management: a systematic examination of the gap from evidence to practice. Pharmacotherapy 2001;21:807-817.
31. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160: 459-467.
32. Rubins HB, Robins SJ, Collins D, Iranmanesh A, Wilt TJ, Mann D, Mayo-Smith M, Faas FH, Elam MB, Rutan GH. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 1995;75: 1196-1201.
33. Schulman KA, Mehta SS, Gersh BJ, Schneider EC, Wilcox CS. Study of Hypertensive Prescribing Practices (SHyPP): A National Survey of Primary Care Physicians. J Clin Hypertens (Greenwich) 1999;1:106-114.
34. Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SC Jr, Alexander CM, Londhe A, Lulla A, Simpson RJ Jr. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999;83:1303-1307.
35. Tonstad S, Rosvold EO, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med 2004;255:494-502.
36. Vale MJ, Jelinek MV, Best JD. How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000. Med J Aust 2002;176:211-215.
37. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996;100:197-204.
38. Wittchen HU, Krause P, Hofler M, Pfister H, Ritz E, Goke B, Lehnert H, Tschope D, Kirch W, Pittrow D, Sharma AM, Bramlage P, Kupper B, Unger T. Hypertension, diabetes mellitus and comorbidity in primary care. Fortschr Med Orig 2003;121(Suppl. 1):19-27.
39. Assmann G, Benecke H, Neiss A, Cullen P, Schulte H, Bestehorn K. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation). Eur J Cardiovasc Prev Rehabil 2006;13:776-783.
40. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002;105: 310-315.
41. Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. BMJ 2005; 331:614.
42. Vasan RS, Larson MG, Leip EP, Evans JC, O'donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-1297.
43. Vasan RS, Sullivan LM, Wilson PW, Sempos CT, Sundstrom J, Kannel WB, Levy D, D'Agostino RB. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005;142: 393-402.
44. Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation 2005;112:3384-3390.
45. Ezzati M, Hoorn SV, Rodgers A, Lopez AD, Mathers CD, Murray CJ. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003;362:271-280.
46. Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications for primary care. Am J Manag Care 1999;5:437-444.
47. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 2000;160:2281-2286.
48. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997;241:317-325.
49. Brindle PM, McConnachie A, Upton MN, Hart CL, Davey SG, Watt GC. The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract 2005;55:838-845.
50. Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999;81:40-46.
51. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.